Dermatology

New late-breaking data showed positive results from the phase 2 trial on a novel septa-specific monoclonal antibody for HS patients.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

New research was conducted into treating Stevens-Johnson syndrome/toxic epidermal necrolysis patients with plasmapheresis before intravenous immunoglobulin therapy.

A new study indicated that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores.

Drs Raj Chovatiya, George Han, and Vivian Shi review the current challenges and opportunities surrounding the utilization and availability of biologic therapies in atopic dermatitis.

Expert dermatologists highlight the burden of atopic dermatitis in young children and examine the clinical data for dupilumab, a biologic treatment for this age group.

The expert panel discusses the heterogeneity of atopic dermatitis manifestation and therapy decisions for individual patients.

Dr Vivian Shi provides an overview of treatment options for atopic dermatitis patients in different age groups.

New data demonstrated that the combined use of prednisone and methotrexate saw positive results in hair regrowth for patients with alopecia totalis or alopecia universalis.

In a research letter, patient perspectives were explored regarding access to dermatology clinic notes, with more than half reporting improved understanding due to notes.

Novan announced on Tuesday that the FDA accepted the New Drug Application (NDA) for Berdazimer Gel, a topical antiviral molluscum contagiosum treatment, for review.

At the AAAAI 2023 Annual Meeting, Dr. Debajyoti Ghosh explains the importance of understanding the effect of phthalates, specifically di-2-ethylhexyl phthalate (DEHP).

New findings have indicated that alopecia areata, alopecia totalis, and alopecia universalis, may disproportionately affect Asian Americans and other people of color.

Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.

Verrica Pharmaceutical's drug-device combination will be decided upon as potentially the first molluscum drug in July.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.